I'll agree. With 6 patients talking percentages is also a waste of time. Still if a number of patients had that type of improvement in the non-study eye I doubt the FDA would ignore the fact that these patients can now see.
The point I was making at the start of this conversation is that if 2 of the 6 patients had that type of improvement, that those results would be surprising given the number of patients on other drugs with that type of response. If you are correct and only 1 patient had that type of improvement then the results would not be as impressive. Still, squalamine seems to have more patients with dramatic improvement then any other drug. I will be calling to see if your Jason was wrong. If I get an aswer I will post it.
Market Data 
Markets 
AI
